The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | A multicenter retrospective analysis of the clinical outcomes of LPL and WM
Matthew Cortese, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, comments on a multicenter retrospective analysis investigating the clinical outcomes of lymphoplasmacytic lymphoma (LPL) and Waldenstrom’s macroglobulinemia (WM). He highlights that outcomes were excellent for patients with LPL, and the number of therapies required did not correspond to a decrement in overall survival. Bendamustine, rituximab, or similar chemoimmunotherapies conferred the most significant benefits in terms of time-to-next treatment. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we also led a retrospective multi-center study looking at outcomes of lymphoplasmacytic lymphoma and Waldenstrom’s macroglobulinemia. My fellow Dr Muhammad Junaid Tariq is our fantastic fellow who’s going to graduate this coming year. He’s going to be a rock star in the lymphoma field. But essentially what we’ve shown with this study is that LPL has excellent outcomes and actually, interestingly enough, the number of therapies that is required actually did not correspond to a decrement in overall survival...
So we also led a retrospective multi-center study looking at outcomes of lymphoplasmacytic lymphoma and Waldenstrom’s macroglobulinemia. My fellow Dr Muhammad Junaid Tariq is our fantastic fellow who’s going to graduate this coming year. He’s going to be a rock star in the lymphoma field. But essentially what we’ve shown with this study is that LPL has excellent outcomes and actually, interestingly enough, the number of therapies that is required actually did not correspond to a decrement in overall survival. We also showed that 20% of patients required no treatment throughout their clinical course measured in decades, and 60% or so have required one line of therapy. Bendamustine, rituxan, or similar chemoimmunotherapies confer the greatest benefits as far as time to next treatment. And then 20% of patients will require multiple lines of treatment as well. So I think it was a very hopefully impactful study, looking at a very rare subtype of non-Hodgkin lymphoma. And it generated a bit of buzz at the end there. And I hope Dr Tariq finds an excellent job. And he did a fantastic work.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
